Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
Clinical trial NCT05429268 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05429268
- Sponsor
- Incyte Corporation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-23
- Primary completion
- 2026-03-30
- Enrollment
- 82
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.